

Real World Studies, LA-SER Research

First published: 23/03/2012

Last updated: 23/03/2012

Institution

Outdated

Other

Institution identification

Institution ID

2484

Institution countries

☐ France

☐ United Kingdom

Type of institution

Other

Institution website

<https://www.LA-SER.com>

ENCePP partner

Yes

Institution description

LA-SER was founded in 2004, with a mission to bring cutting-edge scientific methodology to evaluate the real-world impact of medicines. Our goal is to find for whom and under which conditions of use the drugs will demonstrate best benefit to patients, with minimal harm. For that purpose, we champion observational and pragmatic studies, with an enviable track record of success. We are pioneers in pharmacoepidemiology and populational health impact assessment of medicines. We also use decision analysis, pharmacoeconomics and Other strategy consulting skills to analyse issues and target drugs at their best. LA-SER has a team of over 150 Late-phase Specialists to work alongside the main actors in the medicines world such as drug and devices manufacturers, regulators, payers and interest groups. LA-SER has recently acquired Analytica International, BAP Health and PBE consulting. As a result, LA-SER is now operating with both active consulting and operational teams in 12 countries.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Hayley Chaplin Hayley.Chaplin@la-ser.com

Main

Hayley.Chaplin@la-ser.com

Lamiae Grimaldi lamiae.grimaldi@la-ser.com

Alternate

lamiae.grimaldi@la-ser.com